{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:57:02Z","timestamp":1760245022507},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2004,6,17]],"date-time":"2004-06-17T00:00:00Z","timestamp":1087430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,6,17]],"date-time":"2004-06-17T00:00:00Z","timestamp":1087430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2004,8,1]]},"DOI":"10.1038\/sj.leu.2403413","type":"journal-article","created":{"date-parts":[[2004,6,17]],"date-time":"2004-06-17T13:26:47Z","timestamp":1087478807000},"page":"1347-1349","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Topoisomerase II\u03b1 as a prognostic factor in mantle cell lymphoma"],"prefix":"10.1038","volume":"18","author":[{"given":"P","family":"Korkolopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T P","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,6,17]]},"reference":[{"key":"BF2403413_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/sj.leu.2403387","volume":"18","author":"C Schrader","year":"2004","unstructured":"Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D et al. Topoisomerase II\u03b1 expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004; 18: 1200\u20131206.","journal-title":"Leukemia"},{"key":"BF2403413_CR2","first-page":"168","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2001","unstructured":"Swerdlow SH, Berger F, Isaackson PI, M\u00fcller-Hermelink HK, Nathwani BN, Piris MA et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp 168\u2013170."},{"key":"BF2403413_CR3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"Anon","year":"1997","unstructured":"Anon . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909\u20133918.","journal-title":"Blood"},{"key":"BF2403413_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","volume":"83","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Hiddeman W . Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 71\u201377.","journal-title":"Ann Hematol"},{"key":"BF2403413_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257\u2013262.","journal-title":"Ann Oncol"},{"key":"BF2403413_CR6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/cncr.11838","volume":"98","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, Achonulu SA, Champlin RE . Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. The prognostic value of \u03b22-microglobulin and the tumor score. Cancer 2003; 98: 2630\u20132635.","journal-title":"Cancer"},{"key":"BF2403413_CR7","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","volume":"89","author":"LH Argatoff","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD . Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067\u20132078.","journal-title":"Blood"},{"key":"BF2403413_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","volume":"38","author":"NS Andersen","year":"2002","unstructured":"Andersen NS, Jensen MK, de Nully Brown P, Geisler CH . A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002; 38: 401\u2013408.","journal-title":"Eur J Cancer"},{"key":"BF2403413_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","volume":"82","author":"F Bosch","year":"1998","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA et al. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567\u2013575.","journal-title":"Cancer"},{"key":"BF2403413_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12: 1281\u20131287.","journal-title":"Leukemia"},{"key":"BF2403413_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0959-8049(97)10056-9","volume":"34","author":"R Oinonen","year":"1998","unstructured":"Oinonen R, Fransilla K, Teerenhovi L, Lappalainen K, Elonen E . Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998; 34: 329\u2013336.","journal-title":"Eur J Cancer"},{"key":"BF2403413_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257\u2013262.","journal-title":"Ann Oncol"},{"key":"BF2403413_CR13","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975\u20134981.","journal-title":"Blood"},{"key":"BF2403413_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1034\/j.1600-0609.2002.00551.x","volume":"68","author":"MK Angelopoulou","year":"2002","unstructured":"Angelopoulou MK, Siakantaris MP, Vassilakopoulos TP, Kontopidou FN, Rassidakis G, Dimopoulou MN et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002; 68: 12\u201321.","journal-title":"Eur J Haematol"},{"key":"BF2403413_CR15","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES . Mantle-cell lymphoma. Semin Hematol 1999; 36: 115\u2013127.","journal-title":"Semin Hematol"},{"key":"BF2403413_CR16","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","volume":"87","author":"TC Greiner","year":"1996","unstructured":"Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302\u20134310.","journal-title":"Blood"},{"key":"BF2403413_CR17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","volume":"89","author":"M Pinyol","year":"1997","unstructured":"Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphoma. Blood 1997; 89: 272\u2013280.","journal-title":"Blood"},{"key":"BF2403413_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1365-2559.2001.01036.x","volume":"38","author":"P Korkolopoulou","year":"2001","unstructured":"Korkolopoulou P, Angelopoulou M, Siakantari M, Mitropoulos F, Vassilakopoulos T, Zorzos H et al. Evaluation of DNA topoisomerase II expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001; 38: 45\u201353.","journal-title":"Histopathology"},{"key":"BF2403413_CR19","first-page":"1406","volume":"9","author":"M Provencio","year":"2003","unstructured":"Provencio M, Corbacho C, Salas C, Millan I, Espana P, Bonilla F et al. The topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 1406\u20131411.","journal-title":"Clin Cancer Res"},{"key":"BF2403413_CR20","first-page":"5430","volume":"9","author":"TP Vassilakopoulos","year":"2003","unstructured":"Vassilakopoulos TP, Doussis-Anagnostopoulou I, Angelopoulou MK, Siakantaris MP, Kittas C, Pangalis GA. Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Topoisomerase IIa expression in Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 5430\u20135431.","journal-title":"Clin Cancer Res"},{"key":"BF2403413_CR21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V83.2.517.517","volume":"83","author":"SH Kaufmann","year":"1994","unstructured":"Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517\u2013530.","journal-title":"Blood"},{"key":"BF2403413_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/bjc.1998.377","volume":"77","author":"TAH J\u00e4rvinen","year":"1998","unstructured":"J\u00e4rvinen TAH, Holli K, Kuukasj\u00e4rvi T, Isola JJ . Predictive value of topoisomerase II\u03b1 and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267\u20132273.","journal-title":"Br J Cancer"},{"key":"BF2403413_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle-cell lymphoma. Cancer Cell 2003; 3: 185\u2013197.","journal-title":"Cancer Cell"},{"key":"BF2403413_CR24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","volume":"95","author":"R Chiarle","year":"2000","unstructured":"Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619\u2013626.","journal-title":"Blood"},{"key":"BF2403413_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/sj.leu.2403337","volume":"18","author":"R Letestu","year":"2004","unstructured":"Letestu R, Ugo V, Valensi F, Radford-Weiss I, Nataf J, Levy V et al. Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia 2004; 18: 953\u2013961.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403413","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:45:12Z","timestamp":1648777512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,17]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8,1]]}},"alternative-id":["BF2403413"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403413","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,17]]},"assertion":[{"value":"27 April 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}